SU-DHL-4 Cells

The SU-DHL-4 cell line is derived from a lymphoblast-like cell isolated from the peritoneal effusion of a 38-year-old Caucasian male patient. This cell line represents a model of diffuse large B-cell lymphoma (DLBCL), one of the most common types of non-Hodgkin lymphoma in adults. The establishment of this cell line has provided valuable insights into the biology of DLBCL, especially concerning the cellular and molecular mechanisms underlying lymphomagenesis and tumor progression. In research, SU-DHL-4 cells have been extensively utilized to study the efficacy and mechanism of action of various chemotherapeutic and targeted therapeutic agents, reflecting their importance in lymphoma treatment research. The cells express several key immunophenotypic markers associated with B-cell lineage such as CD19 and CD20, which are crucial for the development and function of B-lymphocytes. These markers also make SU-DHL-4 an excellent target for testing B-cell-specific therapies, including monoclonal antibodies and small molecule inhibitors that disrupt critical signaling pathways involved in lymphoma cell survival and proliferation.